Mobile Health to Improve Adherence and Patient Experience in Heart Transplantation Recipients: The mHeart Trial.
Mar Gomis-PastorSònia MirabetEulalia Roig MinguellVicenç Brossa LoidiLaura Lopez LopezSandra Ros AbarcaElisabeth Galvez TugasNúria Mas-MalagarrigaMª Antonia Mangues BafalluyPublished in: Healthcare (Basel, Switzerland) (2021)
Non-adherence after heart transplantation (HTx) is a significant problem. The main objective of this study was to evaluate if a mHealth strategy is more effective than standard care in improving adherence and patients' experience in heart transplant recipients. Methods: This was a single-center, randomized controlled trial (RCT) in adult recipients >1.5 years post-HTx. Participants were randomized to standard care (control group) or to the mHeart Strategy (intervention group). For patients randomized to the mHeart strategy, multifaceted theory-based interventions were provided during the study period to optimize therapy management using the mHeart mobile application. Patient experience regarding their medication regimens were evaluated in a face-to-face interview. Medication adherence was assessed by performing self-reported questionnaires. A composite adherence score that included the SMAQ questionnaire, the coefficient of variation of drug levels and missing visits was also reported. Results: A total of 134 HTx recipients were randomized (intervention N = 71; control N = 63). Mean follow-up was 1.6 (SD 0.6) years. Improvement in adherence from baseline was significantly higher in the intervention group versus the control group according to the SMAQ questionnaire (85% vs. 46%, OR = 6.7 (2.9; 15.8), p-value < 0.001) and the composite score (51% vs. 23%, OR = 0.3 (0.1; 0.6), p-value = 0.001). Patients' experiences with their drug therapy including knowledge of their medication timing intakes (p-value = 0.019) and the drug indications or uses that they remembered (p-value = 0.003) significantly improved in the intervention versus the control group. Conclusions: In our study, the mHealth-based strategy significantly improved adherence and patient beliefs regarding their medication regimens among the HTx population. The mHeart mobile application was used as a feasible tool for providing long-term, tailor-made interventions to HTx recipients to improve the goals assessed.
Keyphrases
- randomized controlled trial
- end stage renal disease
- healthcare
- ejection fraction
- newly diagnosed
- open label
- chronic kidney disease
- double blind
- phase iii
- study protocol
- heart failure
- mental health
- palliative care
- stem cells
- psychometric properties
- peritoneal dialysis
- phase ii
- magnetic resonance imaging
- placebo controlled
- pain management
- adverse drug
- young adults
- public health
- glycemic control
- weight loss
- chronic pain
- mesenchymal stem cells
- drug induced
- adipose tissue
- atrial fibrillation
- insulin resistance
- replacement therapy
- diffusion weighted imaging